Bimekizumab-Bkzx - Uses, Dosage, Precautions, Side Effects, and Pharmacological Aspects

Overview

Bimekizumab-bkzx was the first FDA (Food and Drug Administration) approved treatment for adults with non-radiographic axial spondyloarthritis (nr-axSpA), a long-lasting condition characterized by inflammation that primarily targets the spine and the sacroiliac joints, which are located where the spine meets the pelvis. The FDA approved Bimekizumab-bkzx on October 18, 2023. There is no other IL-17A or interleukin-17A and IL-17F inhibitor marketed in the US (United States) to treat this condition. Notably, the decrease in the two primary cytokines is associated with reduced inflammation and lessening symptoms such as pain and stiffness, which significantly impacts the quality of life in patients with nr-axSpA.

Drug Group

Bimekizumab-bkzx belongs to the class of biological drugs and is more broadly classified as an interleukin-17A and F antagonist. It binds and neutralizes the interleukin-17A and F, pro-inflammatory cytokines that involve both inflammation and immune response for treating autoimmune diseases.

Indications

Bimekizumab-bkzx, a humanized interleukin-17A and F antagonist, is licensed for treating the following:

• Moderate to severe plaque psoriasis (PSO) (causes red, scaly skin patches) in individuals suitable for systemic or phototherapy (light therapy).

• Active psoriatic arthritis (PsA) (joint inflammation linked to psoriasis) in adults.

• Active non-radiographic axial spondyloarthritis (nraxSpA) (spine inflammation without visible damage on X-rays but with signs of inflammation) in adults with objective signs of inflammation.

• Active ankylosing spondylitis (spine inflammation that can lead to reduced flexibility due to bone fusion) in adults.

Dosage Forms and Available Strengths

Bimekizumab-Bkzx can be administered in a hospital or clinic by a skilled and trained health professional, or the patient may receive proper training on how to use the prefilled syringe or auto-injector and administer the medication at home. The preparation is filled into a prefilled syringe and auto-injector for subcutaneous injection. Following proper training of the patient on its use, they can self-administer the medication at home under the watchful eye of their healthcare provider. However, it can be given in an in-patient setting for patients who need closer monitoring.

Injection: Clear to slightly opalescent solution, colorless to pale brownish-yellow; 160 mg/mL (milligrams per milliliter); available as a single-dose prefilled syringe and a single-dose prefilled auto-injector.

For Patients

How Does the Bimekizumab-Bkzx Work In Nonradiographic Axial Spondyloarthritis (Nr-Axspa)?

The drug Bimekizumab-bkzx targets and blocks specific inflammatory pathways in the disease pathogenesis of non-radiographic axial spondyloarthritis, acting as a mechanism for the described follows:

• Interleukin-17A and 17F Inhibition: Bimekizumab is a monoclonal antibody that blocks the activity of two pro-inflammatory cytokines: IL-17A and IL-17F. Both play a role in driving inflammation in autoimmune diseases, including nr-axSpA.

• Reduction of Inflammation: In nr-axSpA, inflammatory activity is mainly observed in the spine and sacroiliac joints, resulting in pain, stiffness, and restricted mobility. By inhibiting IL-17A and IL-17F, Bimekizumab reduces the underlying inflammation, which helps reduce the symptoms and establishes further prevention of joint destruction.

• Improvement of Symptoms: Patients suffering from nr-axSpA primarily report chronic back pain, stiffness, and fatigue. Bimekizumab's dual inhibition of IL-17A and IL-17F seems to involve a more generalized form of inflammation suppression, thus likely to provide greater symptom relief than treatments targeting only IL-17A.

• Progression Prevention: Though nr-axSpA does not, at least not initially, have visible damage on X-rays as is seen with ankylosing spondylitis, it is strongly associated with marked inflammation. Bimekizumab prevents the progression of the disease by reducing this kind of inflammation, decreasing the risk of secondary complications, and preserving joint function in the long run.

What Are the Side Effects of Bimekizumab-Bkzx?

Here is a list of the side effects associated with Bimekizumab-bkzx based on the information provided:

Common Adverse Reactions

• Upper respiratory infections (URI).

• Oral candidiasis (fungal infection of the mouth).

• Headache.

• Injection site reactions.

• Tinea infections.

• Gastroenteritis (stomach flu).

• Herpes simplex infections.

• Acne.

• Folliculitis (inflammation of follicle).

• Other candida infections.

• Fatigue.

Less Common Adverse Reactions

• Neutropenia (low levels of neutrophils).

• Eczema (red, itchy, and inflamed patches on the skin).

• Otitis externa (an outer ear canal infection or inflammation).

• Otitis media (middle ear infection).

• Pyrexia (fever).

What Are the Things to Inform the Doctor Before Taking Bimekizumab-Bkzx?

Before using Bimekizumab-bkzx, inform your doctor and pharmacist if you are allergic to it or its ingredients.

• Tell the doctor if you are taking prescription or over-the-counter medicines, vitamins, minerals, other dietary supplements, and herbal products. In such instances, it might be necessary for your doctor to adjust dosages or keep a close eye on side effects.

• Inform your doctor if you have any active or chronic infections, including tuberculosis or TB (a contagious bacterial infection affecting the lungs), a history of depression, suicidal thoughts, liver problems, or inflammatory bowel disease like Crohn's disease (a chronic inflammatory bowel disease) or ulcerative colitis (a chronic inflammatory bowel disease that causes inflammation and ulcers in the colon and rectum). Also, mention if you have recently received or are scheduled to get a vaccine.

• Inform the doctor of all prescription and over-the-counter medications, vitamins, diet supplements, and herbal products you are currently taking or intend to take. The doctor may have to adjust dosages or monitor you more closely for side effects.

• Avoid vaccinations without your doctor's approval.

• Be aware that Bimekizumab-bkzx has been linked to suicidal thoughts and behaviors. If you experience new or worsening depression, anxiety, suicidal thoughts, or mood changes, contact your doctor right away.

• Bimekizumab-bkzx may weaken your immune system, increasing the risk of serious infections. Tell your doctor if you often get infections or think you might have one, including minor or chronic infections like herpes (caused by the herpes simplex virus). Call your doctor immediately if you experience fever, chills, muscle aches, or painful skin sores.

• The medication may also increase the risk of developing TB. Let your doctor know if you have had TB, lived in an area where TB is typical, or have been around someone with TB. Your doctor may test for inactive TB and treat it if needed.

• Contact your doctor if you develop symptoms like coughing, blood in mucus, weight loss, fever, or night sweats.

Patient Instructions for Bimekizumab-Bkzx:

• Read Medication Guide: Patients and caregivers should read the FDA-approved medication guide and instructions for use.

• First Injection: The first self-injection should be done under a healthcare professional’s guidance to ensure proper technique.

• Dosage for Plaque Psoriasis: Use two 160 mg syringes or autoinjectors to achieve the 320 mg dose.

• Needle Disposal: Learn proper needle and syringe disposal.

• Suicidal Thoughts: Monitor for suicidal thoughts or mood changes. Contact a healthcare provider if needed.

• Infections: Bimekizumab-bkzx may lower your ability to fight infections. Report any history of diseases or new symptoms to your doctor.

• Liver Monitoring: Bimekizumab-bkzx may increase liver enzyme levels. Get regular liver function tests and contact your doctor if you notice signs of liver issues.

• Bowel Disease: Seek medical advice if Crohn’s disease or ulcerative colitis symptoms develop.

• Vaccinations: Avoid live vaccines during treatment and inform your doctor before getting vaccinated.

• Pregnancy: There is a pregnancy registry for women using Bimekizumab-bkzx during pregnancy to monitor outcomes.

Dietary Considerations

Dietary consideration are only required if recommended by your doctor.

Missed Dose

If a dose is missed, take it as soon as remembered, then follow the regular schedule.

Overdose

If the person collapses, has a seizure (abnormal brain activity), has trouble breathing, or is unresponsive, call the hospital immediately.

Storage and Handling

Bimekizumab-bkzx is a sterile, preservative-free injection solution. Each prefilled autoinjector or syringe contains 160 mg/mL of the solution.

Packaging Options:

• Autoinjector: Two-pack and single-pack.

• Prefilled Syringe: Two-pack and single-pack.

Storage:

Keep refrigerated at two degrees Celsius or °C to eight °C (36 degrees Fahrenheit or °F to 46°F) in original packaging. Do not freeze or shake. If kept at room temperature (up to 25°C or 77°F), use within 30 days and discard any unused portion.

Disposal

Unused or outdated medications, including injections like bimekizumab-bkzx, must be disposed of safely. The FDA recommends using only specifically designated drug take-back programs where available. If those are unavailable, follow the label or medication guide instructions to dispose of the medication properly. To dispose of injectable drugs, place spent needles and syringes in a sharps disposal container rather than household trash. If you have any particular requirements, contact your local garbage management.

For Doctors:

Description:

Bimekizumab-bkzx is a recombinant humanized IgG1 (Immunoglobulin G) monoclonal antibody that acts as an antagonist to interleukin-17 A and F. It is manufactured from a mammalian cell line expressing the recombinant DNA in Chinese Hamster Ovary cells.

What Is the Dosage of Bimekizumab-Bkzx?

Recommended Evaluations and Immunizations Before Starting Bimekizumab-Bkzx:

• TB Testing: Consider testing for latent TB before initiating.

• LFTs (Liver Function Tests): Measures liver enzymes, alkaline phosphatase, and bilirubin.

• Immunizations: Verify that all age-appropriate immunizations are up to date.

Recommended Dose

• For Psoriatic Plaque: Administer 320 mg at weeks 0, 4, 8, 12, and 16, followed by every eight weeks after that. For patients more than or equal to 265 pounds, administer 320 mg every four weeks after week 16.

• Psoriatic Arthritis: 160 mg administered subcutaneously every four weeks.

• Non-Radiographic Axial Spondyloarthritis: 160 mg administered subcutaneously every four weeks.

• Ankylosing Spondylitis: 160 mg subcutaneously every four weeks.

Preparation Instructions

Allow Bimekizumab-bkzx to reach room temperature for 30 to 45 minutes in the carton provided to protect it from light. Then, inspect the solution for clarity and color; do not administer it if it contains particulate matter or is discolored.

How Is Beremagene-Geperpavec-Svdt Administered?

Healthcare professionals should administer Bimekizumab-bkzx, whereas a patient can inject himself if the patient has been appropriately trained.

If two 160 mg injections are to be given, they should be administered at different sites in the thigh, abdomen, or back of the upper arm.

The injection site should not be within two inches of the navel and preferably should not be administered into tender, bruised, or diseased skin. The injection location should be rotated after each injection.

Warnings and Precautions

• Suicidal Ideation and Behavior: Suicidal thoughts and attempts were evaluated in the clinical programs using C-SSRS (Columbia-suicide severity rating scale). It measures the ideation and behavior related to suicidal acts. In two psoriasis plaque treatment studies, there was a higher number of patients in the Bimekizumab-bkzx group that had suicidal thoughts compared to patients in the placebo group (1.8 percent vs. 0.6 percent). For Psoriatic Arthritis, the events were minimal. 0.3 percent in Bimekizumab-bkzx vs. 0.7 percent in the placebo. There was no report of suicidal ideation in the available literature related to non-radiographic axial spondyloarthritis or ankylosing spondylitis. The potential benefits against the risks of Bimekizumab-bkzx should be weighed by physicians for those patients who have had a history of severe depressive illness or suicidal behavior. Educate patients and their families to observe and report mood changes to a physician.

• Infections: Bimekizumab-bkzx may increase the susceptibility to infections. Therapy should only be started in a patient with an active infection if this condition has been adequately treated. Patients with chronic infections should be monitored closely.

• Tuberculosis: Closely evaluate patients for tuberculosis (TB) before initiating Bimekizumab-bkzx. Use with caution in patients with active TB and treat latent TB before starting treatment.

• Hepatic Biochemical Abnormalities: Bimekizumab-bkzx may raise liver enzyme levels. Test ALT (alanine aminotransferase) or AST (aspartate aminotransferase) before initiating and during treatment. If serious liver abnormalities occur, discontinue Bimekizumab-bkzx.

• Inflammatory Bowel Disease: The usage of IL-17 inhibitors such as Bimekizumab-bkzx has been linked to inflammatory bowel disease (IBD). Use with caution in patients with active IBD and consider systemic therapies concurrently; continue monitoring for symptoms.

• Immunizations: All immunizations should be up to date before starting Bk. Avoid the use of live vaccines during treatment with Bk. Limited information exists regarding the concurrent use of non-live vaccines and Bk.

What Are the Pharmacological Actions of Beremagene-Geperpavec-Svdt?

Mechanism of Action: Bimekizumab-bkzx is a humanized IgG1 (immunoglobulin G) monoclonal antibody that specifically targets and binds to interleukin 17A (IL-17A) and interleukin 17F (IL-17F) cytokines, blocking their interaction with the IL-17 receptor complex. By inhibiting these cytokines, which are involved in inflammatory and immune responses, Bimekizumab-bkzx reduces the release of pro-inflammatory cytokines and chemokines.

Pharmacodynamics: Elevated IL-17A and IL-17F levels are found in psoriatic skin lesions. The relationship between Bimekizumab-bkzx exposure and serum biomarker levels of IL-17A and IL-17F is not fully understood. Healthy individuals receiving a single dose of Bimekizumab-bkzx before vaccination with an inactivated influenza vaccine showed similar antibody responses compared to those who did not receive the medication.

Pharmacokinetics: The pharmacokinetics of Bimekizumab-bkzx are similar among diseases, such as plaque psoriasis and psoriatic arthritis. On average, peak plasma concentration is 25 μg/mL (micrograms per milliliter), occurring after three to four days, with dose-proportional pharmacokinetics from 64 to 480 mg.

• Absorption: In healthy subjects, it is bioavailable up to 70 percent.

• Distribution: The steady-state median distribution volume is 11.2 L (liters).

• Elimination: Clearance is achieved with a median of 0.337 L (liters)/day and a half-life of 23 days.

The catabolic pathways are expected to break down the Bimekizumab-bkzx into short peptides.

Specific Populations

No major differences in pharmacokinetics were found based on age (greater than or equal to 18 years). In adults weighing ≥265 pounds, plasma concentration is predicted to be at least 30 pounds lower compared to those weighing (less than) <265 pounds.

Immunogenicity

The incidence of anti-drug antibodies (ADA) varies depending on assay sensitivity. In pivotal trials, the development of ADA was noted:

• Plaque Psoriasis: 45 percent of patients developed ADA, with 16 % showing neutralizing antibodies.

• Psoriatic Arthritis: 47 percent developed ADA, with 18 percent being neutralizing.

• Non-Radiographic Axial Spondyloarthritis: 57 percent had ADA, with 25 percent neutralizing.

• Ankylosing Spondylitis: 44 percent developed ADA, with 20 percent neutralizing.

Overall, the presence of ADA did not significantly affect the safety or effectiveness of Bimekizumab-bkzx.

Non-Clinical Toxicity:

Carcinogenicity and mutagenicity studies for Bimekizumab-bkzx have not been performed. Fertility parameters were not affected in female sexually mature cynomolgus monkeys who received Bimekizumab-bkzx 200 mg/kg/week or milligrams per kilograms per week for 26 weeks: any possible effects on the reproductive organs, length of the menstrual cycle, or sperm count were not affected. The impact of Bimekizumab-bkzx on mating was not studied.

What Are the Contraindications of Bimekizumab-Bkzx?

No contraindications are documented clinically.

What Are the Drug Interactions of Bimekizumab-Bkzx?

CYP450 Substrates

• Increased levels of specific cytokines (IL-1, IL-6, IL-10, TNFα, IFN) in chronic inflammation can alter the production of CYP450 or cytochrome P450. Treatment with the drug bimekizumab-bkzx will affect serum levels of specific cytokines.

• Consequently, when initiating or discontinuing Bimekizumab-bkzx in patients taking other medications that are CYP450 substrates especially those with a narrow therapeutic index—it is advisable to monitor for therapeutic effects (like Warfarin) or drug concentrations (for example, Cyclosporine) and consider adjusting the dosage of the CYP450 substrate.

• Population is pharmacokinetic (PK) analyses revealed that the clearance of Bimekizumab-bkzx is not affected by the concurrent use of conventional DMARDs (disease-modifying anti-rheumatic drugs), including Methotrexate or by previous exposure to biologics.

Clinical Studies

In a clinical trial, the safety and effectiveness of Bimekizumab-bkzx were studied in 254 adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Patients had inflammation and active disease with significant back pain. Most had previously tried NSAIDs (nonsteroidal anti-inflammatory drugs) without success, and some had taken anti-TNF (tumor necrosis factor) medications.

Patients received either Bimekizumab-bkzx 160 mg or a placebo every four weeks for 16 weeks. Results showed that 47.7 percent of Bimekizumab-bkzx patients significantly improved (ASAS 40) compared to 21.4 percent with placebo. Bimekizumab-bkzx also improved pain, inflammation, and overall quality of life.

Use in Specific Populations

Pregnancy: Limited data on Bimekizumab-bkzx in pregnant women makes it difficult to assess risks for birth defects or miscarriage, although it can cross the placenta, particularly in the third trimester. Studies in pregnant monkeys revealed no harmful effects from high doses, and the general risk of birth defects in the U.S. is about two to four percent, with miscarriage risk at 15 to 20 percent. Because Bimekizumab-bkzx may affect immune responses, it is advisable to delay live virus vaccinations for infants exposed in utero for at least four months after birth.

Lactation: There is no data on Bimekizumab-bkzx in breast milk or its effects on breastfed infants. The benefits of breastfeeding should be weighed against the mother's need for Bimekizumab-bkzx and the potential risks to the infant.

Geriatric Use: No overall differences in safety profile were observed among the 1,789 patients treated with Bimekizumab-bkzx, 153 of whom were 65 or older.